- Trial phase
- Phase 2
- Time to market
- Unknown, the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).
- Why 5/10
- The next hard catalyst is initial data from the Phase 2 Duchenne muscular dystrophy (DMD) trial, expected in H1 2027 (~4-10 months away). This is a Phase 2 readout, not a registration-quality binary, and rinvatercept is one of two key pipeline assets (alongside elritercept partnered with Takeda), so the drug is not the sole company value driver. ImpactScore of 5 reflects a mid-stage asset with a dated catalyst within ~12 months at a ~$200M market-cap company.
Watch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.
Price Chart
Executive Summary
Rinvatercept (KER-065) is a clinical-stage TGF-beta ligand trap from Keros Therapeutics (KROS, Nasdaq) designed to promote muscle and bone growth. It has completed Phase 1 testing in healthy volunteers with favorable safety and biomarker data, and a Phase 2 trial in Duchenne muscular dystrophy (DMD) was initiated in Q2 2026 with initial data expected in H1 2027. Regulatory engagement for an ALS trial is planned for H2 2026. Keros has a strong cash position ($257.6M, runway into H1 2028) and a $1.3B+ Takeda partnership for its other asset elritercept. The stock trades near its 52-week low (~$11.23) with a mean analyst price target of ~$19.83, but rinvatercept remains an early-stage, binary-risk program with no near-term pivotal readouts.
How It Works
Rinvatercept is a protein-based drug (a ligand trap) designed to block certain signaling molecules in the TGF-beta family that normally limit muscle growth and bone formation. By blocking these signals, rinvatercept aims to promote muscle mass increase and bone density improvement, potentially beneficial in muscle-wasting diseases like Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).
Trial Status
Phase 1 completed in healthy volunteers (data presented March 2026 at MDA Clinical & Scientific Conference). Phase 2 DMD trial initiated in Q2 2026; initial data expected H1 2027. Regulatory engagement for an ALS Phase 2 trial planned for H2 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 DMD trial initial data, expected H1 2027
- ALS regulatory engagement / Phase 2 trial initiation, planned H2 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Keros Therapeutics, Inc. PRESS-RELEASE KROS ·Originating report